Benzinga··PrnewswireSoligenix Wins EMA Backing for SGX945 Orphan Drug Status in Behçet's Disease
Soligenix wins EMA orphan drug designation backing for SGX945 treating Behçet's Disease, following positive Phase 2a results and prior FDA support.
SNGXrare diseaseclinical trial